IPF Longitudinal Natural History Study
Natural History and Temporal Dynamics of Idiopathic Pulmonary Fibrosis: A Longitudinal Cohort Study With Structured Disease Stratification
This is a longitudinal observational cohort study of patients with idiopathic pulmonary fibrosis (IPF) conducted within the Assiut University IPF Research Program between 2022 and 2026. The study aims to characterize the natural history, temporal disease dynamics, event patterns, and clinical outcomes of IPF over a two-year follow-up period.
Primary analyses focus on disease progression, acute exacerbation, hospitalization, mortality, and final clinical state. Secondary analyses include prespecified evaluation of the Inflammatory Burnout Index (IBI; Zenodo DOI: 10.5281/zenodo.18843181) and the Severity-Phenotype-Dynamics integration framework (SPD; Zenodo DOI: 10.5281/zenodo.18843362) as observational analytical frameworks for disease activity and multidimensional disease characterization. These frameworks are applied for research stratification only and do not influence treatment allocation, clinical management, or follow-up decisions.
調査の概要
状態
条件
詳細な説明
This observational cohort study follows patients with idiopathic pulmonary fibrosis using predefined longitudinal clinical, physiological, radiological, and outcome assessments. The study is designed to describe disease burden, temporal progression, event distribution, and end-state outcomes in a real-world IPF cohort.
Eligible participants are adults with a clinical and radiological diagnosis of IPF according to standard diagnostic assessment, with available baseline evaluation and planned longitudinal follow-up. Patients are followed for up to two years to document acute exacerbations, respiratory hospitalization, functional decline, mortality, and final clinical status.
The study includes secondary analytical evaluation of two predefined disease-characterization frameworks. The Inflammatory Burnout Index (IBI) is used to evaluate dynamic inflammatory-fibrotic balance and functional reserve. The SPD framework integrates disease severity, phenotype, and dynamic disease behavior into a multidimensional observational stratification structure. Both frameworks are archived with Zenodo DOIs and are evaluated without modifying patient care.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Asyut、エジプト、71515
- Faculty Of Medicine - Assiut University Hospitals - Assiut - Egypt
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Adults aged ≥18 years.
- Diagnosis of idiopathic pulmonary fibrosis based on clinical and radiological assessment according to standard guidelines.
- Availability of baseline clinical, functional, and radiological evaluation.
- Enrollment within the Assiut University IPF Research Program.
- Ability to undergo longitudinal follow-up and outcome assessment.
Exclusion Criteria:
- Interstitial lung disease other than idiopathic pulmonary fibrosis
- Alternative diagnosis inconsistent with IPF based on clinical or radiological evaluation
- Incomplete baseline data preventing cohort classification
- Refusal to participate or inability to complete follow-up
- End-stage disease at baseline requiring invasive mechanical ventilation or terminal care
- Active malignancy or severe comorbidity expected to dominate short-term prognosis
- Long-term systemic immunosuppressive therapy not aligned with standard IPF management
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Idiopathic Pulmonary Fibrosis Cohort
This cohort includes adult patients with idiopathic pulmonary fibrosis enrolled in a longitudinal observational study conducted between 2022 and 2026 at Assiut University.
Participants undergo predefined follow-up assessments to document clinical outcomes, including disease progression, acute exacerbations, hospitalization, and mortality.
No interventions are assigned, and all data are collected as part of routine clinical care and structured observational follow-up.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to First Composite Clinical Event (Acute Exacerbation, Hospitalization, or Death) in 24 months
時間枠：24 months
|
Time from cohort entry (baseline enrollment) to the first occurrence of any of the following events: acute exacerbation of idiopathic pulmonary fibrosis, respiratory-related hospitalization, or all-cause mortality.
Events are prospectively recorded during longitudinal follow-up within the study period.
|
24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to First Acute Exacerbation of Idiopathic Pulmonary Fibrosis
時間枠：Up to 24 months
|
Time from baseline enrollment to the first occurrence of acute exacerbation of idiopathic pulmonary fibrosis during follow-up.
|
Up to 24 months
|
|
Time to First Respiratory-Related Hospitalization
時間枠：Up to 24 months
|
Time from baseline to first hospitalization related to respiratory deterioration or acute exacerbation.
|
Up to 24 months
|
|
All-Cause Mortality
時間枠：Up to 24 months
|
Occurrence of death from any cause during the study follow-up period.
|
Up to 24 months
|
|
Inflammatory Burnout Index (IBI)-Defined Disease Activity
時間枠：Up to 12 months
|
Evaluation of disease activity using the Inflammatory Burnout Index (IBI), a predefined analytical framework for dynamic disease characterization (Zenodo DOI: 10.5281/zenodo.18843181).
Applied observationally without influencing clinical management.
|
Up to 12 months
|
|
Severity-Phenotype-Dynamics (SPD) Integrated Disease States
時間枠：Up to 24 months
|
Assessment of integrated disease states using the Severity-Phenotype-Dynamics (SPD) framework combining severity, phenotype, and dynamic disease behavior (Zenodo DOI: 10.5281/zenodo.18843362).
Applied for observational stratification only.
|
Up to 24 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Aliae A. Hussien, MD、Assiut University
- 主任研究者：Ahmad M. Shaddad, MD、Assiut University
- 主任研究者：Maiada K. Hashem, MD、Assiut University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2025-23-4
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data underlying the results reported in this study will not be publicly shared. Data are governed by the Assiut University IPF Research Program policies and institutional regulations. De-identified data may be considered for sharing upon reasonable request to the corresponding investigator, subject to institutional review, ethical approval, and execution of a formal data use agreement.
Analytical code and model specifications are not publicly distributed. Access may be considered under controlled conditions in accordance with institutional policy, intellectual property considerations, and approved collaborative agreements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。